2020
Primary melanotic tumors of the nervous system: a consecutive case series
Grosshans H, Huttner A, Piepmeier J, Kaulen L, Fulbright R, Baehring J, Karschnia P. Primary melanotic tumors of the nervous system: a consecutive case series. European Journal Of Neurology 2020, 27: 2303-2307. PMID: 32654331, DOI: 10.1111/ene.14437.Peer-Reviewed Original ResearchMeSH KeywordsHumansImmunohistochemistryMagnetic Resonance ImagingMelaninsNervous System NeoplasmsRetrospective StudiesConceptsPrimary melanotic tumorsNervous systemRelapsed diseaseClinical presentationMelanotic lesionsFavorable outcomeRadiation therapyPre-contrast T1-weighted imagingRelative incidenceMelanotic tumorsHomogenous contrast enhancementYale Cancer CenterAggressive surgical treatmentConsecutive case seriesPsammomatous melanotic schwannomaNervous system tumorsT1-weighted imagingT2-weighted imagingTumor mass effectMagnetic resonance imagingMelanin-containing cellsS100 positivitySurgical resectionSurgical treatmentTumor Registry
2008
Intracranial benign fibrous histiocytomas: a case report and review
Moliterno JA, Sood S, Zambrano E, Kim JH, Piepmeier JM, Baehring JM. Intracranial benign fibrous histiocytomas: a case report and review. Journal Of Neuro-Oncology 2008, 92: 203-209. PMID: 19030779, DOI: 10.1007/s11060-008-9743-x.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsChildFemaleHistiocytoma, Benign FibrousHumansImmunohistochemistryMicroscopy, Electron, TransmissionNeurosurgical ProceduresSeizures
1996
Targeting microtubule-associated proteins in glioblastoma: A new strategy for selective therapy
Piepmeier J, Pedersen P, Yoshida D, Greer C. Targeting microtubule-associated proteins in glioblastoma: A new strategy for selective therapy. Annals Of Surgical Oncology 1996, 3: 543-549. PMID: 8915486, DOI: 10.1007/bf02306087.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, AlkylatingBrain NeoplasmsCarrier ProteinsCell LineColony-Forming Units AssayEstramustineFlow CytometryGlioblastomaHumansImmunohistochemistryMiceMice, NudeMicrotubule-Associated ProteinsNeoplasm TransplantationRadiation-Sensitizing AgentsThymidineTransplantation, HeterologousTumor Cells, CulturedConceptsSubcutaneous xenograftsGlioblastoma cellsHuman glioblastoma cellsMicrotubule-associated proteinsHuman glioblastomaPotent antimitotic effectsUse of estramustineAntimicrotubule agentsEstramustine-binding proteinPreclinical dataEstramustineNeoplastic cellsAntiproliferative effectsSelective therapyGlioma cellsAntimitotic effectCytotoxic effectsGlioblastomaUseful targetTherapyXenograftsLaboratory investigationsSelective effectAntimitotic activityCells
1995
Verapamil treatment attenuates immunoreactive GFAP at cerebral cortical lesion site
Klepper S, Naftolin F, Piepmeier J. Verapamil treatment attenuates immunoreactive GFAP at cerebral cortical lesion site. Brain Research 1995, 695: 245-249. PMID: 8556338, DOI: 10.1016/0006-8993(95)00825-b.Peer-Reviewed Original ResearchConceptsGFAP-like immunoreactivityGlial fibrillary acidic proteinSaline groupCortical lesionsLocal injectionNeedle lesionsLesion siteL-type calcium channel blockerCerebral cortical lesionsCortical lesion sitesL-type calcium channelsCalcium channel blockersSprague-Dawley ratsImmunoreactive glial fibrillary acidic proteinTime of lesioningFibrillary acidic proteinH post lesionTransmembrane calcium fluxVerapamil treatmentReactive astrocytesPost lesionContralateral hemisphereChannel blockersCalcium channelsAntigen labeling